Nano Cap New Millennium Growth Fund L P Acquires New Holdings in Personalis, Inc. $PSNL

Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Personalis, Inc. (NASDAQ:PSNL) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 290,000 shares of the company’s stock, valued at approximately $2,308,000. Personalis makes up 2.0% of Nano Cap New Millennium Growth Fund L P’s portfolio, making the stock its 8th biggest holding.

Several other institutional investors also recently bought and sold shares of the business. Legal & General Group Plc purchased a new position in Personalis in the second quarter worth $30,000. International Assets Investment Management LLC purchased a new position in Personalis in the fourth quarter worth $31,000. BNP Paribas Financial Markets grew its holdings in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares during the last quarter. Focus Partners Wealth purchased a new position in Personalis in the first quarter worth $47,000. Finally, FourThought Financial Partners LLC purchased a new position in Personalis in the third quarter worth $86,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Trading Up 3.8%

NASDAQ:PSNL opened at $8.25 on Friday. Personalis, Inc. has a 12 month low of $3.84 and a 12 month high of $11.50. The firm has a fifty day simple moving average of $6.55 and a 200-day simple moving average of $8.03. The company has a market capitalization of $863.94 million, a P/E ratio of -8.09 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.49 million. Equities analysts forecast that Personalis, Inc. will post -1.06 EPS for the current year.

Analyst Ratings Changes

PSNL has been the topic of several analyst reports. Guggenheim lifted their price target on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. BTIG Research cut their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Finally, Morgan Stanley cut their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.